Novocure (NVCR) has received approval from the FDA for its new Head Flexible Electrode (HFE) transducer arrays, which are to be utilized with Optune Gio in treating adult patients with glioblastoma multiforme. Novocure intends to transition Optune Gio users in the United States to the new HFE arrays by the first half of 2025, following a structured transition plan.
Mukund Paravasthu, Chief Operating Officer of Novocure, stated, "The newly approved HFE arrays by the FDA are lighter, thinner, and designed to enhance comfort, offering clear advantages for patients. We are eager to introduce these new arrays in the U.S."
